| Literature DB >> 33837096 |
Sara Calderón Larrañaga1,2, Megan Clinch3, Trisha Greenhalgh4, Sarah Finer3,5.
Abstract
INTRODUCTION: Social prescribing is an innovation being widely adopted within the UK National Health Service policy as a way of improving the management of people with long-term conditions, such as type 2 diabetes (T2D). It generally involves linking patients in primary care with non-medical community-based interventions. Despite widespread national support, evidence for the effectiveness of social prescribing is both insufficient and contested. In this study, we will investigate whether social prescribing can contribute to T2D prevention and, if so, when, how and in what circumstances it might best be introduced. METHODS AND ANALYSIS: We will draw on realist evaluation to investigate the complex interpersonal, organisational, social and policy contexts in which social prescribing relevant to T2D prevention is implemented. We will set up a stakeholder group to advise us throughout the study, which will be conducted over three interconnected stages. In stage 1, we will undertake a realist review to synthesise the current evidence base for social prescribing. In stage 2, we will investigate how social prescribing relevant to people at high risk of T2D 'works' in a multiethnic, socioeconomically diverse community and any interactions with existing T2D prevention services using qualitative, quantitative and realist methods. In stage 3 and building on previous stages, we will synthesise a 'transferable framework' that will guide implementation and evaluation of social prescribing relevant to T2D prevention at scale. ETHICS AND DISSEMINATION: National Health Service ethics approval has been granted (reference 20/LO/0713). This project will potentially inform the adaptation of social prescribing services to better meet the needs of people at high risk of T2D in socioeconomically deprived areas. Findings may also be transferable to other long-term conditions. Dissemination will be undertaken as a continuous process, supported by the stakeholder group. Tailored outputs will target the following audiences: (1) service providers and commissioners; (2) people at high risk of T2D and community stakeholders; and (3) policy and strategic decision makers. PROSPERO REGISTRATION NUMBER: CRD42020196259. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.Entities:
Keywords: diabetes & endocrinology; primary care; social medicine
Mesh:
Year: 2021 PMID: 33837096 PMCID: PMC8043019 DOI: 10.1136/bmjopen-2020-042303
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Multilevel and dynamic realist framework. C, context; M, mechanism; O, outcome.
Figure 2Overview of the study design. T2D, type 2 diabetes.
Overview of data source and collection in stage 2
| Data source | Data collection |
| SP service users | Interviews: Approximately 2 focus groups and 7 in-depth interviews. Purposive sampling, based on ethnicity, gender, age, diabetes risk, participation in SP. |
| Clinical data on all Tower Hamlets residents eligible for SP: Clinical measurements (HbA1c). Diagnosis codes (listed in QOF, including hypertension, diabetes, obesity). Disease risk (QRISK2, QDScore, pre-diabetes). | |
| Sociodemographic data on all Tower Hamlets residents eligible for SP: Age and gender. Ethnicity. Ethnic density of local geography (postcode). Country of birth. First language spoken. Socioeconomic status (index of multiple deprivation, by lower layer super output area). | |
| Primary care professionals, including link workers | Interviews: Approximately 2 focus groups and 7 in-depth interviews. Purposive sampling based on professional profile, type of contract, demographic characteristics (age, gender, ethnicity). |
| SP referrers’ quantitative data: Demographic characteristics (age and gender). Primary care workers’ professional profile and background. Type of contract. | |
| VCS organisations | Interviews: Approximately 2 focus groups and 7 in-depth interviews. Purposive sampling based on type of activities, community embeddedness. |
| Observations of SP activities. | |
| Key documentation: protocols, referral templates, advertising, web pages, and so on. | |
| SP providers’ quantitative data: Characteristics of the VCS organisations: available resources, areas of interest. Patients’ attendance frequency. | |
| SP service | Overview of the SP service: Existing referral criteria and reasons for referral. Number of referrals per network, surgery, health worker and profession. |
| Health economic data, including: Staff contact. Attendance rates. Facility use. | |
| Policy makers and public health stakeholders | Interviews: Approximately 5 semistructured interviews. Snowball sampling. |
| Key documents and policy reports on SP. |
QOF, Quality and Outcomes Framework; SP, social prescribing; VCS, voluntary and community sector.